SUMMARY
Generics in China industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY FINDINGS
Essential resource for top-line data and analysis covering the China generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
REASONS TO BUY
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The Chinese generics market is expected to generate total revenues of $63.1bn in 2016, representing a compound annual growth rate (CAGR) of 15.5% between 2012 and 2016.
Market consumption volume is forecast to decline with a compound annual rate of change (CARC) of -0.2% between 2012 and 2016, to reach a total of 94.3% of total pharma volume in 2016.
The Chinese government has announced an ambitious universal healthcare program that aims to provide healthcare for the country's 1.3 billion inhabitants. This should ensure further growth for the market.
NOTE: Out of security concerns MarketLine requires using corporate email address.
Generics in China industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY FINDINGS
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in China
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in China
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the China generics market with five year forecasts by both value and volume
Essential resource for top-line data and analysis covering the China generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
REASONS TO BUY
- What was the size of the China generics market by value in 2016?
- What will be the size of the China generics market in 2021?
- What factors are affecting the strength of competition in the China generics market?
- How has the market performed over the last five years?
- How large is China's generics market in relation to its regional counterparts?
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The Chinese generics market is expected to generate total revenues of $63.1bn in 2016, representing a compound annual growth rate (CAGR) of 15.5% between 2012 and 2016.
Market consumption volume is forecast to decline with a compound annual rate of change (CARC) of -0.2% between 2012 and 2016, to reach a total of 94.3% of total pharma volume in 2016.
The Chinese government has announced an ambitious universal healthcare program that aims to provide healthcare for the country's 1.3 billion inhabitants. This should ensure further growth for the market.
NOTE: Out of security concerns MarketLine requires using corporate email address.
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
China Grand Pharmaceutical and Healthcare Holdings Limited
Mylan Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
China Grand Pharmaceutical and Healthcare Holdings Limited
Mylan Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
LIST OF TABLES
Table 1: China generics market value: $ billion, 2012-16(e)
Table 2: China generics market volume: % of total pharma volume, 2012-16(e)
Table 3: China generics market geography segmentation: $ billion, 2016(e)
Table 4: China generics market value forecast: $ billion, 2016-21
Table 5: China generics market volume forecast: % of total pharma volume, 2016-21
Table 6: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 7: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 8: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 9: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 10: Mylan Inc.: key facts
Table 11: Mylan Inc.: key financials ($)
Table 12: Mylan Inc.: key financial ratios
Table 13: Sandoz International GmbH: key facts
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios
Table 17: China size of population (million), 2012-16
Table 18: China gdp (constant 2005 prices, $ billion), 2012-16
Table 19: China gdp (current prices, $ billion), 2012-16
Table 20: China inflation, 2012-16
Table 21: China consumer price index (absolute), 2012-16
Table 22: China exchange rate, 2012-16
Table 1: China generics market value: $ billion, 2012-16(e)
Table 2: China generics market volume: % of total pharma volume, 2012-16(e)
Table 3: China generics market geography segmentation: $ billion, 2016(e)
Table 4: China generics market value forecast: $ billion, 2016-21
Table 5: China generics market volume forecast: % of total pharma volume, 2016-21
Table 6: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 7: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 8: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 9: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 10: Mylan Inc.: key facts
Table 11: Mylan Inc.: key financials ($)
Table 12: Mylan Inc.: key financial ratios
Table 13: Sandoz International GmbH: key facts
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios
Table 17: China size of population (million), 2012-16
Table 18: China gdp (constant 2005 prices, $ billion), 2012-16
Table 19: China gdp (current prices, $ billion), 2012-16
Table 20: China inflation, 2012-16
Table 21: China consumer price index (absolute), 2012-16
Table 22: China exchange rate, 2012-16
LIST OF FIGURES
Figure 1: China generics market value: $ billion, 2012-16(e)
Figure 2: China generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: China generics market geography segmentation: % share, by value, 2016(e)
Figure 4: China generics market value forecast: $ billion, 2016-21
Figure 5: China generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in China, 2016
Figure 7: Drivers of buyer power in the generics market in China, 2016
Figure 8: Drivers of supplier power in the generics market in China, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in China, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in China, 2016
Figure 11: Drivers of degree of rivalry in the generics market in China, 2016
Figure 12: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues and profitability
Figure 13: China Grand Pharmaceutical and Healthcare Holdings Limited: assets and liabilities
Figure 14: Mylan Inc.: revenues and profitability
Figure 15: Mylan Inc.: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities
COMPANIES MENTIONED
China Grand Pharmaceutical and Healthcare Holdings Limited
Mylan Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Skip to top
Figure 1: China generics market value: $ billion, 2012-16(e)
Figure 2: China generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: China generics market geography segmentation: % share, by value, 2016(e)
Figure 4: China generics market value forecast: $ billion, 2016-21
Figure 5: China generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in China, 2016
Figure 7: Drivers of buyer power in the generics market in China, 2016
Figure 8: Drivers of supplier power in the generics market in China, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in China, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in China, 2016
Figure 11: Drivers of degree of rivalry in the generics market in China, 2016
Figure 12: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues and profitability
Figure 13: China Grand Pharmaceutical and Healthcare Holdings Limited: assets and liabilities
Figure 14: Mylan Inc.: revenues and profitability
Figure 15: Mylan Inc.: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities
COMPANIES MENTIONED
China Grand Pharmaceutical and Healthcare Holdings Limited
Mylan Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Nano-Enabled Packaging for the Pharmaceutical Industry: a Technology, Industry and Market Analysis
US$ 3,250.00
Mar, 2010 · 93 pages
